Product details
Background：Tezepelumab is a first-in-class human monoclonal antibody that binds to TSLP, thus inhibiting its interaction with TSLP receptor complex. Tezepelumab given as an add-on-therapy to patients with severe uncontrolled asthma has shown safety, tolerability and efficacy. Several trials are evaluating the long-term safety and the efficacy of tezepelumab in adults and adolescents with severe uncontrolled asthma.
• Thymic Stromal Lymphopoietin (TSLP), Its Isoforms and the Interplay with the Epithelium in Allergy and Asthma., PMID:37628907
• Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma., PMID:32567399
• Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD., PMID:36697211
• Role of thymic stromal lymphopoietin in allergy and beyond., PMID:35650271
• IL-31-generating network in atopic dermatitis comprising macrophages, basophils, thymic stromal lymphopoietin, and periostin., PMID:36410530
• Serum thymic stromal lymphopoietin (TSLP) levels in atopic dermatitis patients: a systematic review and meta-analysis., PMID:37515689
• Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target Therapy., PMID:38892164
• Investigational thymic stromal lymphopoietin inhibitors for the treatment of asthma: a systematic review., PMID:38206116
• Pathogenesis of allergic diseases and implications for therapeutic interventions., PMID:36964157
• Thymic stromal lymphopoietin (TSLP) is a substrate for tryptase in patients with mastocytosis., PMID:37500310
